Cosmo Pharmaceuticals N.V. provided earnings guidance for the year 2022. For the year, the company expects Total revenues in the range of 90 million to 100 million against 65.1 million in 2021. Operating profit in the range of 20 million to 25 million against 7 million to 10 million in 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.6 CHF | -0.97% | -3.76% | +40.67% |
26/04 | Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 | CI |
25/04 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.67% | 1.26B | |
+29.68% | 681B | |
+25.07% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+14.68% | 235B | |
+4.71% | 199B | |
-12.43% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- COPN Stock
- News Cosmo Pharmaceuticals N.V.
- Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2022